News and Trends 9 Jan 2023
Selecta and Astellas sign LOPD treatment agreement
Selecta Biosciences, Inc. and Astellas Pharma Inc. have announced an exclusive licensing and development agreement for IdeXork (Xork). Xork is being studied as a potential next generation immunoglobulin G (IgG)…